Lower tumor mutational burden (TMB), a lower number of tumor-infiltrating lymphocytes (TILs), and poor response to ICI have also been reported for EGFR-mutated NSCLC [25,26,27], and any potential role of ICI in cases with EGFR mutations is currently discussed [28]. This evidence concerns the gene EGFR and neoplasm.